Pharmafile Logo

News and Press Releases

Microbiotica Announces Positive Results from its Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma

MB097 used in combination with MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) 18 May 2026 -- Cambridge, UK -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 18, 2026

Microbiotica
info@microbiotica.com
Microbiotica Limited Chesterford Research Park Little Chesterford Cambridge CB10 1XL UK

AES Cleanroom Technology Marks 40 Years of Innovation at INTERPHEX 2026

21 April 2026 -- Pennsylvania, US -- AES Cleanroom Technology, a leading provider of modular cleanroom design, manufacturing, and construction solutions for the life sciences and biopharmaceutical industries, is celebrating...

Category: Biotechnology, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: April 21, 2026

AES Clean Technology
422 Stump Road, Montgomeryville, PA 18936

University of Colorado Grants License to Cirena for RNA-Synthesis Technology

Foundational synthesis technology enables scalable modified 100-400nt RNA constructs, speeding design cycles and improving genome-editing precision 10 March 2026 -- Colorado, US -- Cirena has secured a license to the...

Category: Biotechnology, Drug Discovery, Manufacturing and Packing, Other
Posted: March 10, 2026

Cirena
rnatechsupport@cirena.com
3415 Colorado Avenue Boulder, CO 80303

SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America

New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform Collaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares’ leadership in biosimilars across...

Category: Biotechnology, Manufacturing and Packing, Other
Posted: March 10, 2026

SteinCares
general@steincares.com
San José, Escazú, Edificio Meridiano 5th floor, Costa Rica

Emmes Coordinates Groundbreaking Stem-Cell Ophthalmology Trial

18 February 2026 -- Maryland, US -- Emmes, a full-service, global Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation – in collaboration with the UC Davis Eye...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 18, 2026

Emmes
401 North Washington Street Suite 700 Rockville, MD 20850

FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference

Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD 17 February 2026 -- Heidelberg, Germany -- FundaMental Pharma GmbH, a preclinical-stage...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: February 17, 2026

FundaMental Pharma
info@fundamentalpharma.com
Nikola-Tesla-Straße 1 D-69124 Heidelberg / Germany

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

European Commission grants approval for Gotenfia, a golimumab biosimilar to Simponi that was developed by Bio-Thera and will be marketed by STADA Launch preparations are underway to bring the second...

Category: BioManufacturing, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: February 13, 2026

STADA
info@stada.de

Samsung Bioepis Reaches Settlement Agreement for Eylea (Aflibercept) Biosimilar in Europe and the Rest of the World

30 January 2026 -- Incheon, Korea -- Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Regeneron and Bayer concerning the commercialization of SB15, a biosimilar to...

Category: Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2026

Samsung Bioepis
76, Songdogyoyuk-ro, Yeonsu-gu, Incheon

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference

Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030 The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 15, 2026

Samsung Bioepis
76, Songdogyoyuk-ro, Yeonsu-gu, Incheon

Immuthera Announces Global Exclusive License from City of Hope for First-in-Class CD6/CTLA-4 CAR-Treg Platform for Autoimmune and Inflammatory Diseases

Global exclusivity for Type 1 Diabetes, Rheumatoid Arthritis, 8 Dermatological Autoimmune diseases, and 13 Neuroinflammatory Autoimmune diseases Six patients with Chronic Graft versus Host Disease treated to-date with a favorable...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026

Immuthera
office@immuthera.bio

Samsung Bioepis Begins Commercialization of BYOOVIZ, Biosimilar to Lucentis (Ranibizumab), in Europe

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI...

Category: Logistics, Other, Pharmaceutical
Posted: January 2, 2026

Samsung Bioepis
76, Songdogyoyuk-ro, Yeonsu-gu, Incheon

Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025

Valiltramiprosate Demonstrates Potential as the First Oral Disease-Modifying Agent to Slow Alzheimer’s Pathology, Indicated by Both Clinical and Volumetric MRI Data Nine Posters Showcase Consistent Benefits of Oral Valiltramiprosate in...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 19, 2025

Alzheon
111 Speen Street, Suite 306 Framingham, MA 01701

Thermo Fisher Scientific Showcases Enhanced Accelerator Drug Development Capabilities and OpenAI Strategic Collaboration at CPHI Frankfurt 2025

Company highlights its global expertise and new and expanded capabilities to help biopharma and biotech customers solve global health challenges 27 October 2025 -- Frankfurt, Germany -- Thermo Fisher Scientific...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 27, 2025

Thermo Fisher Scientific
168 Third Avenue Waltham, MA 02451

Horus Pharma announces strategic Agreement to commercialize Formycon’s Aflibercept Biosimilar FYB203 under the brand name Baiama across Key European Markets including its Home Market France

23 October 2025 -- Nice, France -- Horus Pharma, the second largest independent ophthalmological laboratory in France and a leading player in Europe, today announced that it has entered into...

Category: Logistics, Other, Pharmaceutical
Posted: October 23, 2025

Horus Pharma
contact@horus-pharma.fr
22 allée Camille MUFFAT - Inedi 5 06200 Nice

CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Editing Platform

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile The AATD program, CTX460, is the first investigational candidate to emerge from the SyNTase editing platform...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 10, 2025

CRISPR Therapeutics
info@crisprtx.com
105 West First Street South Boston, MA 02127 617-315-4600